1. Home
  2. IKT vs HAVA Comparison

IKT vs HAVA Comparison

Compare IKT & HAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.39

Market Cap

209.3M

Sector

Health Care

ML Signal

N/A

HAVA

Harvard Ave Acquisition Corporation Class A Ordinary Share

SELL

Current Price

$10.29

Market Cap

209.0M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
IKT
HAVA
Founded
2008
2024
Country
United States
South Korea
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.3M
209.0M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
IKT
HAVA
Price
$1.39
$10.29
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $5.55
N/A
AVG Volume (30 Days)
★ 518.1K
69.8K
Earning Date
11-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 57.76
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$9.90
52 Week High
$2.61
$10.30

Technical Indicators

Market Signals
Indicator
IKT
HAVA
Relative Strength Index (RSI) 36.37 68.54
Support Level N/A $9.98
Resistance Level $1.71 $10.30
Average True Range (ATR) 0.12 0.00
MACD 0.00 -0.00
Stochastic Oscillator 2.82 83.33

Price Performance

Historical Comparison
IKT
HAVA

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share

Harvard Ave Acquisition Corp is a blank check company.

Share on Social Networks: